Headquartered in San Diego, CA Fiscal year ends June NYSE: RMD resmed.com
ResMed Inc. (NYSE: RMD, ASX: RMD) is a global medical device and digital health company focused on sleep-disordered breathing, respiratory care, and residential care software. The company develops and manufactures cloud-connected devices, masks, and accessories for the treatment of obstructive sleep apnea and other respiratory conditions, serving patients in over 140 countries. Its product portfolio includes the AirSense and AirCurve device platforms and a range of mask systems. ResMed also operates a Residential Care Software business (including MatrixCare, which is being divested) that provides technology solutions for out-of-hospital care settings. The company integrates AI-powered digital health solutions and intelligent software to personalize and improve home healthcare delivery. ResMed recently acquired Noctrix Health, expanding into wearable therapeutics for Restless Leg Syndrome. Updated
Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold moves on names like Eli Lilly, Etsy, Northrop Grumman, and Rivian. Find out which stocks got upgraded,…
Pre-Market Stock Futures: Futures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX | SPCX Price Prediction) or SpaceX IPO rush is starting to fade…
Friday's top analyst upgrades and downgrades included Carvana, Chevron, Dynatrace, Exxon Mobil, First Solar, Mastercard, MGM Resorts International, Shopify, Snowflake, Target and Welltower.
Wednesday's top analyst upgrades and downgrades included American Eagle Outfitters, Apple, Coinbase, DoorDash, Estee Lauder, Gap, Goldman Sachs, Meta Platforms, Rivian Automotive, Shopify, SoFi Technologies, Tapestry, TechnipFMC, Uber Technologies, Valley National Bancorp…
Wednesday's top analyst upgrades and downgrades included Chevron, Cleveland-Cliffs, Infosys, Knight-Swift Transportation, Microsoft, Nucor, Salesforce, Steel Dynamics, Wheaton Precious Metals and Zoom Video Communications.
Monday's top analyst upgrades and downgrades included Altria, Archer Daniels Midland, Baidu, Beyond Meat, Bunge, General Electric, Hecla Mining, Kraft Heinz, Lowe’s Companies, Mosaic, Philip Morris International, Rivian Automotive, SLM, Sunrun, Toast,…
Wednesday's top analyst upgrades and downgrades included BP, ConocoPhillips, Equity Residential, Exxon Mobil, Global Payments, Kroger, Microsoft, NRG Energy, RingCentral, Valero Energy, Wayfair, Wendy's and Workday.
Monday's top analyst upgrades and downgrades included Altria, Amazon.com, Apple, Axalta Coating Systems, Comcast, Etsy, Intel, McDonald's and Medical Properties Trust.
Friday’s additional top analyst upgrades and downgrades were on Axalta Coating Systems, Caterpillar, DigitalOcean, Edwards Lifesciences, First Solar, Gilead Sciences, Intel, Stanley Black & Decker, Unity Software, Western Union and more.
Thursday's top analyst upgrades and downgrades included Albertsons Companies, Ally Financial, Datadog, Dominion Energy, Oracle, Southern, Spotify Technology, Sunnova Energy, Sunrun and Xcel Energy.
Monday's additional top analyst upgrades and downgrades were on Academy Sports and Outdoors, Charter Communications, Comcast, Dollar General, Southwest Airlines, Truist Financial, Vroom and more.
Friday's additional top analyst upgrades and downgrades were on Ciena, Lennar, Lexicon Pharmaceuticals, Mister Car Wash, PagerDuty, RealReal, Six Flags and more.
RBC Capital Markets takes a look at a few stocks with potentially huge upside, and where they could go in light of a possible recession.
Monday’s additional top analyst upgrades and downgrades were on American Express, Aurora Cannabis, Edison International, Eli Lilly, PayPal, Upwork and more.
Monday's top analyst upgrades and downgrades included Amazon.com, Apple, Caterpillar, Comcast, Comerica, Gilead Sciences, Intel, Lululemon Athletica and McDonald's.
ResMed Inc. (NYSE: RMD, ASX: RMD) is a global medical device and digital health company focused on sleep-disordered breathing, respiratory care, and residential care software.
24/7 Wall St.'s 12-month price target for RMD is $271.62, rated Buy. The Wall Street consensus target is $250.52. RMD price prediction →
